These investments will meet growing global demand for frozen and freeze-dried Direct Vat Inoculants (DVI) and reinforce Danisco’s leading market position as a cultures supplier.
The additional capacities will be located in North America, where Danisco is transforming a former enzyme production unit from its Genencor Division into a cultures plant, and in Europe.
With 9% sales growth and 23% profitability growth compared to last year, Danisco Cultures Division is experiencing rapidly increasing market demand as more dairy manufacturers convert from traditional bulk starter cultures to the more reliable DVI solutions.
The steep demand growth curve is also fuelled by the continuous rise of the health & nutrition market, particularly for probiotic cultures in dietary supplements and functional foods, the development of natural food protective solutions as well as the mainstream trend towards more natural and sustainable products as cultures benefit from consumer-friendly labelling.
Furthermore, the acquisition in 2008 of the US company Agtech Products marked an important strategic step towards broadening Danisco Cultures’ market penetration by bringing cultures for animal nutrition and other non-food markets into the company portfolio.
“This is a significant investment from Danisco, which demonstrates the Group’s long-term commitment to be our customers’ first choice for their needs in state-of-the-art, affordable cultures,” said Fabienne Saadane-Oaks, Danisco Bio Actives president.
© FoodBev Media Ltd 2020